Get started
Author

Mirjam de With

Observed names: M. De With, M. de With, de With, Mirjam
ORCID: 0000-0002-9953-7945
Observed ORCID: 0000-0002-9953-7945
OpenAlex ID: A5049769702
CYP3A4∗22 Genotyping in Clinical Practice: Ready for Implementation?
2021 · Tessa A. M. Mulder, Ruben A. G. van Eerden, et al. · Frontiers in Genetics · 86
PDF
Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe
2023 · M. de With, A. Sadlon, et al. · ESMO Open · 77
PDF
UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients
2022 · Emma C. Hulshof, Mirjam de With, et al. · European Journal of Cancer · 64
PDF
Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study
2022 · Mirjam de With, Jonathan Knikman, et al. · Clinical Pharmacology & Therapeutics · 60
PDF
Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy
2021 · Tessa A. M. Mulder, Mirjam de With, et al. · Cancers · 58
PDF
Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy
2021 · Mirjam de With, Daan P. Hurkmans, et al. · Cancers · 29
PDF
Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1
2023 · Mirjam de With, Leni van Doorn, et al. · Clinical Pharmacokinetics · 24
PDF
Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer
2022 · Niels Heersche, G.D. Marijn Veerman, et al. · Drug Resistance Updates · 24
PDF
Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study
2018 · Femke M. de Man, Koen G.A.M. Hussaarts, et al. · Clinical Pharmacology & Therapeutics · 22
PDF
Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD
2023 · Mirjam de With, Leni van Doorn, et al. · Biomedicine & Pharmacotherapy · 21
Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study
2025 · Jonathan E. Knikman, Mirjam de With, et al. · European Journal of Cancer · 15
The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer
2020 · Bodine P. S. Belderbos, Mirjam de With, et al. · Cancer Chemotherapy and Pharmacology · 6
Effects of Pharmacogenetic Variants on Vemurafenib-related Toxicities in Patients with Melanoma
2019 · Andrew KL Goey, Mirjam de With, et al. · Pharmacogenomics · 6
DPYD*7 as a Predictor of Severe Fluoropyrimidine-Related Adverse Events
2022 · Mirjam de With, Gemma Brufau, et al. · JCO Precision Oncology · 5
Real-World Impact of UGT1A1 Genotype–Guided Irinotecan Dosing on Severe Toxicity and Hospitalization: A Multicenter Study
2026 · Niels Heersche, Sofía L.J. Peeters, et al. · Journal of the National Comprehensive Cancer Network · 4
Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan.
2021 · Emma C. Hulshof, Mirjam de With, et al. · Journal of Clinical Oncology · 4
Survival of patients with colorectal or pancreatic cancer who received UGT1A1 genotype-guided dosing of irinotecan in the Netherlands (2017–2024): a retrospective, multicentre cohort study
2026 · Sofía L.J. Peeters, Niels Heersche, et al. · The Lancet Regional Health - Europe · 2
596P Dose-individualisation of fluoropyrimidines in DPYD wild-type patients: Final results from the Alpe2U study
2024 · N. Heersche, J.E. Knikman, et al. · Annals of Oncology · 1
PDF
70P Fluoropyrimidine (FP) dose individualization based on pretreatment uracil levels: Safety and pharmacokinetic (PK) analysis from the Alpe2U study
2022 · M. De With, J. Knikman, et al. · Annals of Oncology · 1
Influence of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib
2018 · F.M. de Man, K.G.A.M. Hussaarts, et al. · Annals of Oncology · 1
PDF
Predictors of poor treatment tolerability in older patients receiving fluoropyrimidine-based chemotherapy: A prospective cohort study
2026 · Joosje C. Baltussen, Jonathan E. Knikman, et al. · Journal of Geriatric Oncology
PDF
NP-012 Survival of patients with colorectal or pancreatic cancer who received UGT1A1 genotype-guided dosing of irinotecan: a multicentre real-world study
2026 · Sofía LJ Peeters, Niels Heersche, et al. · European Journal of Hospital Pharmacy
1686eP Local skin reactions due to topical 5-fluorouracil treatment: Does DPYD-genotype matter?
2025 · N. Heersche, M. de With, et al. · Annals of Oncology
2238P Survival outcomes after UGT1A1 genotype-guided dosing of irinotecan: Results of a multicentre survival analysis
2025 · N. Heersche, S.L.J. Peeters, et al. · Annals of Oncology
PDF
Response to “Plasma Uracil as a DPD Phenotyping Test: Pre‐analytical Handling Matters”
2022 · Mirjam de With, Jonathan Knikman, et al. · Clinical Pharmacology & Therapeutics
PDF
Works count: 31
Citation count: 510
H-index: 11
I10-index: 11
Year
Topic
Type